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Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone
marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the
myeloablative (MA) conditioning consisted of thiotepa, busulfan, ﬂudarabine (n ¼ 35), or total body irradi-
ation (TBI), ﬂudarabine (n ¼ 15). The median age was 42 years (range, 18-66 years); 23 patients were in
remission, 27 had active disease, and 10 patients were receiving a second allograft. Graft-versus-host disease
(GVHD) prophylaxis consisted in PT-CY on day þ3 and þ5, cyclosporine (from day 0), and mycophenolate
(from day þ1). Three patients died before engraftment, and 2 patients had autologous recovery: 45 patients
(90%) had full-donor chimerism on day þ30. The median day for neutrophil engraftment was day þ18 (range,
13-30 days). The cumulative incidence of grade II-III acute GVHD (aGVHD) was 12%, and of moderate chronic
GVHD (cGVHD) 10%. With a median follow-up for surviving patients of 333 days (range, 149-623 days), the
cumulative incidence of transplantation-related mortality (TRM) was 18%, and the rate of relapse was 26%.
The actuarial 22-month disease-free survival (DFS) rate was 68% for patients in remission and 37% for patients
with active disease (P < .001). Causes of death were pneumonia (n ¼ 3), hemorrhage (n ¼ 3), sepsis (n ¼ 3),
and relapse (n ¼ 7). In conclusion, an MA conditioning regimen followed by haploidentical BMT with PT-CY
results in a low risk of aGVHD and cGVHD and encouraging rates of TRM and DFS.
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In 2010, the World Marrow Donor Association reported
46,919 activations of unrelated donor (URD) searches
worldwide and 16,858 transplantations, including peripheral
blood, cord blood, and bone marrow (BM; World Marrow
Donor Association report 2011). Also allowing for nonurgent
donor searches, at least 50% of patients with leukemia are
not ﬁnding a suitable URD in time. Haploidentical family
transplantations represent an important alternative, as
shown by the Perugia and other groups, mostly looking at
CD34 selected or T cell depleted grafts [1-3]. These studies
have highlighted the importance of natural killer (NK) cells in
this setting [1,2] as well as problems connectedwith immune
reconstitution and infectious complications. Several studies
using haploidentical unmanipulated peripheral blood or BM
as a stem cell source have been recently reported [4-6]. In
one of these programs [5], a nonmyeloablative conditioning
regimen was followed by unmanipulated haplomismatched
bone marrow transplantation (BMT), posttransplantation
high-dose cyclophosphamide (PT-CY), and tacrolimus,
mycophenolate mofetil (MMF) after the last dose of PT-CY. A
high rate of stable engraftment could be documented
together with a low risk of graft-versus-host disease (GVHD)dgments on page 122.
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12.08.014lymphocytes are activated after the infusion into the recip-
ient, enter a proliferative phase, and are thus sensitive to the
cytotoxic effect of cyclophosphamide 72 hours later. On the
other hand, nonalloreactive, nonproliferating T cells are
spared the purging effect of PT-CY [7,8], and may provide
protection against infections in the short term and allow for
a more robust immune reconstitution. Furthermore, PT-CY
does not affect engraftment because of the enzymatic resis-
tance of hemopoietic stem cells to cyclophosphamide [9].
The problem with a nonmyeloablative conditioning regimen
is that the relapse rate is high, particularly using PT-CY. In
a recent comparison of the same conditioning regimen fol-
lowed by a cord blood transplantation, or haplomismatched
transplantation with PT-CY [10], relapse rates were signiﬁ-
cantly higher in the haplomismatched group.
However, it is possible that a myeloablative (MA) regimen
followed by PT-CY would reduce the risk of relapse, in
keeping with 2 large registry-based studies showing that MA
regimens are superior to reduced-intensity conditioning
regimens in preventing relapse of the original disease [11,12].
We are now reporting the use of PT-CY in the context of
an MA conditioning regimen with haploidentical T cell
replete BM, in patients with high-risk hematological
malignancies.
PATIENTS AND METHODS
Patients
This is a retrospective study on 50 patients with hematologic malig-
nancies who received an MA regimen with PT-CY between July 2010 andTransplantation.
Table 1
Patients and Graft Characteristics
Number of patients 50
Median age in years 42 (18-66)
Gender (male/female) 31/19
Diagnosis
AML 25
ALL 12
Lymphoma 5
PMF 4
CML 3
MPD 1
Disease phase
CR1 11
CR2 12
Active disease 27
Previous autograft 2
Previous allograft 10
CMV serology
Dþ/Rþ 37
D/Rþ 6
Dþ/R 4
D/R 3
Graft composition
Nucleated cells  108/kg 3.6 (1.4-7.7)
CD34þ cells  106/kg 4.0 (0.08-10)
CD3þ cells  106 35 (0.7-163)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
PMF, primary myeloﬁbrosis; CML, chronic myeloid leukemia; MPD,
myeloproliferative disease; CR, complete remission; CMV, cytomegalovirus;
Dþ/Rþ, CMV positive donor/CMV positive recipient; D/Rþ, CMV negative
donor/CMV positive recipient; Dþ/R, CMV positive donor/CMV negative
recipient; D/R, CMV negative donor/CMV negative recipient.
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and were provided signed informed consents. Clinical data are summarized
in Table 1. A total of 27 patients had active disease at transplantation, and 23
were in hematologic remission; 10 patients had failed a previous allogeneic
transplantation (4 had chemorefractory disease). The most common diag-
nosis was acute myeloid leukemia (AML) (n ¼ 25), 9 patients were in ﬁrst
complete remission (CR1), 6 of these were high-risk AML (more lines of
induction therapy and/or Fms-related thyrosine kinase 3 FLTþ and/or
complex karyotype), 7 patients were in CR beyond the ﬁrst (4 relapsed
postallotransplantation and 2 postautotransplantation). A total of 9 patients
with AML had refractory disease (4 with primary refractory disease, 5 with
refractory relapse). Of 12 patients with acute lymphoblastic leukemia (ALL),
2 patients were in CR1, 6 were in second CR (2 relapsed post-
allotransplantation), and 4 had chemorefractory disease (1 relapsed post-
allotransplantation). Of 4 patients with lymphoma, all were in
chemorefractory disease. Two patients had leukemic transformation of
primary myeloﬁbrosis (PMF). All 3 patients with chronic myelogenous
leukemia were in blast crisis, unresponsive to tyrosine kinase inhibitors.
HLA
All donor/patient pairs were genotypically haplomismatched: this
included mismatching in the GVHD direction for 3 (n ¼ 35), 2 (n ¼ 14), or 1
(n¼ 1) HLA-A, HLA-B, or HLA-DR antigens andmismatching for 3 (n¼ 34), 2
(n ¼ 9), or 1 (n ¼ 5) HLA-A, HLA-B, or HLA-DR antigens in the host-versus-
graft direction. A single patient, because of HLA homozygosity, had
0 mismatches in the graft-versus-host direction and 3 mismatched in the
host-versus-graft direction.
Conditioning Regimen and GVHD Prophylaxis
The MA conditioning regimen was based on either chemotherapy
(thiotepa, busulfan, ﬂudarabine [TBF]) or total body irradiation (TBI) and
ﬂudarabine (F-TBI). The choice of the conditioning was based on the
patient’s age, restricting TBI to patients under the age of 56, and onwhether
they had already received a previous allogeneic graft with TBI in the
conditioning. Twenty-seven patients received the TBF regimen, which
included thiotepa (Tepadine; Adienne, Bergamo, Italy) 5 mg/kg on days 6
and 5 (total dose 10 mg/kg), ﬂudarabine (Fludara; Sanoﬁ Aventis, France)
50 mg/m2 on days 4, 3, and 2 (total dose 150 mg/m2), and busulfan
(Busilvex; Pierre Fabre, Paris, France) 3.2 mg/kg i.v. on days 4, 3, and 2
(total dose 9.6 mg/kg). Fifteen patients received the F-TBI regimen, which
included TBI 3.3 Gy on days 8, 7, and 6 (total dose 9.9 Gy) and ﬂudar-
abine 30 mg/m2 on days 5, 4, 3, and 2 (total dose 120 mg/m2). Forelderly patients (>60 years), or patients in poor clinical condition, the days
of busulfan administrationwere reduced from 3 to 2 days (n¼ 7) or to 1 day
(n ¼ 1). GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg on
day þ3 and þ5, cyclosporine A (CSA) 1 mg/kg given as a continuous i.v.
infusion from day 0 to day þ20, adjusting for blood levels (200-400 ng/mL),
and then orally until day þ180; MMF (15 mg/kg q12h) from day þ1 to
day þ28. Pegylated granulocyte colony-stimulating factor 1 vial s.c. (6 mg)
was given on day þ5 to all patients. Mesna (80% of the cyclophosphamide
dose) was administrated in 3 divided doses from day þ3 daily through
day þ7. All dosing was based on ideal body weight. Phenytoin, 300 mg
prescribed orally was administered on all days of busulfan therapy. Ten
advanced patients (5 with AML) received 1 course of chemotherapy 2 weeks
before the start of the conditioning regimen.
Stem Cell Source
Unmanipulated BM was used as a stem cell source for all patients and
infused i.v. on day 0. Donors underwent BM harvest while under general
anesthesia, and the ideal target of mononuclear cells was 4  108/kg of
recipient body weight.
Supportive Care
Antimicrobial prophylaxis was started during the conditioning regimen
and consisted of acyclovir 500 mg/m2 3 times a day, levoﬂoxacin 500 mg
a day, and ﬂuconazole 400 mg per day until day þ75. Biweekly cytomega-
lovirus (CMV) monitoring by PCR or antigenemia was started on day 7,
until dayþ100 and weekly until dayþ180. Weekly EpsteineBarr virus (EBV)
monitoring by PCR was started on dayþ15, as described by Coppoletta et al.
[13].
Diagnosis and Treatment of GVHD
The clinical diagnosis of acute GVHD (aGVHD) was made according to
standard criteria and conﬁrmed histologically by skin and/or rectal biopsies.
First-line therapy of GVHD was methylprednisolone 1 to 2 mg/kg day;
second-line therapy was extracorporeal photopheresis, MMF, corticoste-
roids, or monoclonal Abs, as per institutional protocols.
Statistical Analysis
The NCSS 2004 software forWindows (NCSS, Kaysville, UT) was used for
chi-square tables, rank-sum 2 samples nonmatched pair test, cumulative
incidence (CI) rates, and actuarial survival. In calculating the CI rates of
transplantation-related mortality (TRM), the competing risk was relapse;
when calculating relapse, the competing risk was TRM. When calculating
neutrophil, platelet recovery, and GVHD, the competing risk was death.
Events for disease-free survival (DFS) were relapse of the original disease or
death, whichever occurred ﬁrst.
RESULTS
Engraftment and Transplant Related Complications
The median number of nucleated BM cells infused was
3.6  108/kg (range, 1.4-7.7), the median number of infused
CD34þ cells was 4.0  106 (range, 0.08-10), and the number
of CD3þ cells was 35  106/kg (range, 0.7-163). The median
time to neutrophil counts of>0.5109/L was 18 days (range,
13-30 days) and to platelet counts of >20  109/L 23 days
(range, 14-58 days), respectively (Figure 1). There was no
correlation between the infused number of nucleated cells
and days of neutrophil engraftment: the median day of
engraftment was 18 days both for patients receiving less or
3.6  108 cells/kg. The same was true for the number of
infused CD34þ cells. Three patients died before engraftment
could be evaluated: 2 of them died within þ10 days of
cerebral hemorrhage, 1 died before engraftment from
Legionella pneumonia, 2 patients (1 AML and 1 PMF) had
autologous recovery on ﬁrst determination of chimerism on
day þ30, 45 patients (90%) had full-donor chimerism of both
unmanipulated BM as well as selected peripheral blood
CD3þ cells. The cumulative incidence of engraftment was
90% for neutrophils on day þ32 and 86% for platelets on
day þ60 (Figure 1).
Transplantation-related complications and infections are
outlined in Table 2. Hepatic sinusoidal obstructive syndrome
developed in 1 patient (2%) and resolved with deﬁbrotide
Figure 1. Cumulative incidence of neutrophil recovery (upper left), platelet recovery (upper right), acute graft-versus-host disease (GVHD) grade II-III (lower left),
and moderate chronic GVHD (lower right).
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Hemorrhagic cystitis developed in 20 patients (40%); 16 of 35
were prepared with busulfan (46%), 4 of 15 were prepared
with TBI (27%) (P ¼ .20), and 5 patients required bladder
irrigation. BK virus was detected in 13 patients (65%) andwas
treated with cidofovir. Cystitis resolved in all 20 patients. A
total of 4 patients had evidence of pericarditis (9%), and 1
patient required surgical drainage; all 4 patients recovered,
and there was no evident infectious cause. CMV reactivation
occurred in 25 patients (50%) and CMV disease in 2 patients
(1 colitis and 1 pneumonia). CMV was detected in 18 of 35
CMV-positive donors in CMV-positive recipients (Dþ/Rþ)
patients (51%), in 5 of 6 D/Rþ patients (83%), in 2 of 4 Dþ/Table 2
Complications and Infections
Number of Patients 50 (%)
SOS 1 (2)
Mucositis grade III 3 (6)
Hemorrhagic cystitis
Mild 15 (30)
Requiring irrigation 5 (10)
Pericarditis 4 (8)
Bacterial infections
Gþ sepsis 13 (26)
G-sepsis 9 (18)
Legionella (pn) 1 (2)
Viral infections
CMV reactivation 25 (50)
EBV reactivation 4 (8)
Adenovirus (pn) 1 (2)
HHV6 viremia 1 (2)
Invasive fungal infections
Aspergillus 5 (10)
Candida krusei sepsis 2 (4)
Fusarium 1 (2)
SOS indicates sinusoidal obstructive syndrome; Gþ, Gram-positive; pn,
pneumonia; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV, human
herpesvirus.R patients (50%), and in none of 3 D/R patients (0%). The
median time of CMV reactivation was þ39 days (range, 3-60
days). EBV DNAemiawas detected in 4 patients, and 1 patient
with EBV-related biopsy-proven gastritis was diagnosed and
treated with rituximab. One patient developed adenovirus
pneumonia. One patient developed human herpes virus 6
viremia. Nineteen patients developed sepsis, occasionally
with more than 1 causative agent: 9 gram-negative sepsis
(E. coli ¼ 6, Enterobacteriacae ¼ 1, Corynebacterium ¼ 1, and
Pseudomonas aeruginosa ¼ 1); 13 gram-positive sepsis (the
most important are: 2 Streptococcus viridans and 3 Entero-
coccus faecium). Invasive fungal infection were seen in 9
patients (5 with Aspergillus pneumonia, 2 Candida krusei
sepsis, and 1 Fusarium). Infections were the primary cause of
death in 6 patients (12%), 3 sepsis and 3 pneumonia
(Legionella, adenovirus, and Invasive aspergillosis).
Immunological Reconstitution
The median lymphocyte counts, stratiﬁed by CD3þ,
CD4þ, CD8þ, and CD56/CD16 is depicted in Figure 2. On
day þ100 median CD3þ, CD4þ, CD8þ, and CD56/CD16þ
counts were respectively, 436, 140, 332, and 158/cmm.
Themedian IgA serum levels were 37mg/dL on dayþ100,
57 mg/dL on day þ180, and 136 mg/dL on day þ365.
Graft-versus-Host Disease
Forty-eight patients were alive on day þ15 and evaluable
for aGVHD: 10 patients (21%) developed grade I aGVHD, 3
grade II (6%), and 3 developed developed grade III (6%). The
CI rate of grade II-III aGVHD was 12%, and no patient devel-
oped grade IV aGVHD (Table 3 and Figure 1). There was no
correlation between the number of infused CD3þ cells and
aGVHD: the CI rate of grade II-III aGVHDwas 12% for patients
receiving less ormore than themedian number of CD3þ cells
(35  106/kg). Thirty-seven patients were evaluable for
chronic GVHD (cGVHD). The CI rate of cGVHD was 26%:
Figure 3. Cumulative incidence (CI) of transplantation-related mortality
(TRM) in patients stratiﬁed for disease phase. There is a trend for a lower TRM
in complete response (CR)1 þ CR2 patients (9%) as compared to patients with
active disease (26%) (P ¼ .10).
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Figure 2. Immune reconstitution after transplantation shown as median cell
counts/cmm: CD4þ cells are 39, 113, 140, 197, and 213/cmm, respectively, on
days þ30, þ60, þ100, þ150, and þ180. On day þ100, CD3þ cells are 436/cmm,
CD8þ cells are 332/cmm, and natural killer (NK) cells are 158/cmm.
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moderate cGVHD in 4 of 37 patients (10%) (Figure 1); the
median time of onset of cGVHD was day þ120 from BMT.
There were 3 overlap syndromes. There were no deaths
primarily because of GVHD.Transplantation-Related Mortality
The cumulative incidence of TRM at 6 months was 18%,
most of the events occurring early (median day þ68), with 1
outlier on dayþ168. The CI rate of TRMwas 9% for patients in
remission and 26% for patients in relapse (P ¼ .10) (Table 3
and Figure 3). There was a trend for a lower mortality in
patients receiving a higher number of BM cells: TRMwas 22%
for patients receiving <3.6  108/kg (n ¼ 27) and 13% for
patients receiving 3.6  108/kg (n ¼ 23) (P ¼ .30). TRM was
comparable in patients receiving chemotherapy or TBI-based
conditioning. Causes of death were pneumonia (n ¼ 3),
hemorrhage (n ¼ 3), and sepsis (n ¼ 3).Relapse
The CI rate of relapse was 22%, 17% for remission patients,
and 33% for patients grafted in relapse (P ¼ .03) (Figure 4).
Of the 4 relapses for patients in remission, 2 were
a second allogeneic transplantation and 1 was a secondTable 3
Clinical Outcome of Patients
Follow-up of surviving patients in days 303 (119-596)
Engraftment
Day of neutrophil 0.5  109/L 18 (13-30)
Day of platelet 20  109/L 23 (14-58)
aGVHD
Grade 0-I 44 (88%)
Grade II-III 6 (12%)
cGVHD
No 18 74%
Minimal 6 16%
Moderate 4 10%
Severe 0 0%
Day þ100 TRM n ¼ 8 (16%)
Overall TRM n ¼ 9 (18%)
Relapse n ¼ 13 (26%)
Relapse-related death n ¼ 7 (14%)
Surviving n ¼ 34 (68%)
Follow-up 333 days (149-623)
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease; TRM, transplantation-related mortality.remission of ALL. Relapse-related death was 5% for patients
in remission and 22% for patients in relapse (P ¼ .02).
Survival and DFS
With a median follow-up of over 8 months (range, 4-22
months), the actuarial overall survival and DFS at 18 months
from transplantation was 62% and 51%, respectively. DFS is
68% for patients in remission and 37% for patients grafted
with active disease (Figure 5). A total of 14 patients (52%)
with active disease at transplantation were alive, and 11
patients (41%) were in remission. Among patients with AML,
18 (72%) were alive and in remission. In univariate analysis,
the only predictor of DFS was disease phase, with a relative
risk of 5.5 of dying for patients with active disease as
compared to patients in remission (95% conﬁdence interval,
2-16).
DISCUSSION
We have shown in this study that BMT from hap-
loidentical donors after an MA conditioning and PT-CY,
allows for a high rate of engraftment, with acceptable TRMFigure 4. Cumulative incidence (CI) of transplantation-related mortality
(TRM) in patients stratiﬁed for disease phase. There is a trend for a lower TRM
in complete response (CR)1 þ CR2 patients (17%) as compared to patients with
active disease (33%) (P ¼ .10).
Figure 5. Disease-free survival (DFS) in CR1 þ CR2 patients (68%) is signiﬁ-
cantly superior to DFS in patients grafted with active disease (37%) (P ¼ .002).
CR, complete response.
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proportion of patients with hematologic malignancies.
As to the ﬁrst point, engraftment is a relevant issue in
haploidentical transplantations [1-3]. In the present study,
full-donor chimerism was documented in 45 patients (90%)
on day þ30 after transplantation; 2 patients had autologous
recovery, and 3 were not evaluable. Neutrophil recovery
(0.5  109/L) was observed at a median interval from trans-
plantation of 18 days, and the median number of WBCs on
day þ50 was 3.6  109/L. Platelet engraftment (20  109/L)
was also rapid (23 days) and complete with a median platelet
count of 75  109/L on day þ50. Hematologic recovery has
been reported to be slower after URD transplantations and
PT-CY in the absence of a calcineurin inhibitor and MMF: 25
days for neutrophil and 35 days for platelet recovery [14],
despite adequate numbers of nucleated cells infused. The
time to neutrophil and platelet engraftment seen in the
present study is similar to our own experience with MA
transplantations from URD (18 days, unpublished); we also
found comparable WBC counts (3.6  109/L and 4.2  109/L)
and platelet counts (75  109/L and 75  109/L) on day þ50
after hematopoietic stem cell transplant from haploidentical
or URD transplantations. We could not show a correlation
between the number of infused nucleated BM cells or CD34þ
cells and speed of hematologic recovery, suggesting that
engraftment and recovery can be achieved also using a cell
dose lower than our median (3.6  108/kg).
Despite a relatively rapid neutrophil recovery, we did see
a number of blood stream infections in 19 patients (38% of 50
patients); however, this ﬁgure is quite similar to what we
have observed in a previous 2004 to 2007 study in which
a blood stream infection was diagnosed in 83 patients of 170
alternative donor transplantations (48%) [15]. Therefore,
engraftment was rapid and complete in evaluable patients,
and infectious complications were comparable to other
standard alternative donor transplantations.
Immune reconstitution is an additional issue of concern
for patients undergoing alternative donor transplantation
[16]. In a previous report, patients receiving a URD graft had
median CD4þ lymphocyte counts on days þ100 and þ150,
respectively, of 45/mL and 63/mL [16]. In the present study,
CD4þ lymphocyte counts at the same time intervals were
140/mL and 197/mL, suggesting that immune recovery is not
slower with PT-CY and perhaps faster. Similar counts havebeen observedwith the double-step approach and high-dose
CY [17]. In keeping with this observation, we saw little EBV
DNAemia, and 1 single case of EBV-associated gastritis,
detected by gastroscopy and successfully treated with rit-
uximab. CMV reactivation occurred in 50% of patients and
CMV disease in 2 patients. The incidence of invasive asper-
gillosis was 10%, somewhat lower than the 15% previously
reported in our unit for alternative donor transplantations
[18].
Cases of aGVHD and cGVHD were seen in a minority of
patients, 12% for aGVHD, and 10% for moderate cGVHD. These
ﬁgures are not higher than in transplantations from other
alternative donors andwere also similar to URD receiving PT-
CYas the sole immunosuppression [14]. No patient died from
GVHD, and only 3 patients required second-line therapy for
aGVHD because of incomplete response. Although we used
BM cells in all of our haplotransplantations, the number of
infused T cells was signiﬁcant ranging from 0.7 to 163  106
CD3þ cells/kg. There was no difference in the CI of aGVHD in
patients receiving lower or higher doses of haploidentical T
cells. The risk of aGVHD grade II-IVwith this program (12%) is
signiﬁcantly lower than the 59% reported with the 2-step
approach [17] and the 40% of the granulocyte colony-
stimulating factor mobilized blood and marrow regimen [4].
Overall, we were impressed with the low, in most instances
absent, aGVHD in a setting of MA conditioning and HLA
mismatched unmanipulated grafts.
Transplantation mortality is the ultimate indicator of
whether a program is well tolerated and leads to good
hematologic and immunologic recovery with acceptable
GVHD. In the present study, TRM was 9% for patients in
remission and 26% for patients with active disease, with an
overall CI of 18%. This is in the low range of TRM reported for
unmanipulated MA haploidentical transplantations: 29% for
the 2-step approach with high-dose CY [17], 22% in the
combined blood and marrow transplantations reported by
Lu et al. [4], 17% reported for URD transplantations with PT-
CY alone [14], and 30% for the MA approach with intensive
GVHD prophylaxis, consisting of antithymocyte globulin,
basiliximab, CSA, methotrexate, and MMF [19]. TRM was
comparable in patients receiving the chemotherapy or the
radiation-based regimen. We gave cyclophosphamide on
days þ3 and þ5, rather than on days þ3 and þ4, as in the
Baltimore program [5]. As patients can be ill after the rela-
tively large dose of CYon day þ3, we also believed 1-day rest
might be important, especially because CSA was started on
day 0, and wewere in no hurry of delivering the second dose
of CY to prevent GVHD. Despite the 1-day rest between the 2
doses of CY, we saw 4 patients with pericarditis (8%), possibly
due to cyclophosphamide toxicity. In patients exposed to
several previous courses of chemotherapy, all of them
responded to treatment. We also saw 20 patients with
hemorrhagic cystitis (40%) with a trend for a higher inci-
dence when given busulfan as compared to radiation.
One ﬁnal crucial problem faced in all transplantation
settings is relapse of the original disease. This is particularly
true with PT-CY in the context of non-MA conditioning,
which has led to a signiﬁcant rate of leukemia relapse [10].
For this reason, we decided to use an MA approach, based on
either a combination high-dose thiotepa and busulfan or TBI.
The TBF regimen was originally described in the context of
cord blood transplantations [20] and has already been used
in other unmanipulated haploidentical transplantation
settings [19]. The TBI-based conditioning is a fractionated
regimenwe have been using for several decades, particularly
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have seen an overall CI of relapse of 22%, with a low risk for
remission patients (17%) and an acceptable risk of relapse
(33%) for patients grafted with active disease. This suggests
that the use of MA conditioning, in the context of haplo-
transplantations and PT-CY, can induce long-term remissions
comparable to conventional unrelated transplantations. DFS
was 68% for 23 patients grafted in remission; of these, a small
number were in ﬁrst remission (n ¼ 11), and their DFS is
currently 90%. Of the 27 patients grafted with active disease,
the current DFS is 37%, which is comparable to our data using
URDs. Whether the use of cyclosporine from day 0 may have
spared some donor lymphocytes the effect of cyclophos-
phamide purging, and thus have fostered graft-versus-
leukemia, remains to be proven. We cannot comment, at
present, on the role of NK cells in alloreactive donors on
relapse because of the small number of patients and small
number of events. DFS for other MA regimens and unma-
nipulated haplotransplantations are 64% for the blood and
marrow approach [4] and 48% with the 2-step program [17].
In conclusion, we have shown that MA conditioning fol-
lowed by haploidentical family mismatched BM and PT-CY
and cyclosporine from day zero, is associated with encour-
aging outcome in terms of engraftment, GVHD, TRM, and
relapse. We have currently initiated a noninferiority study, in
which we will prospectively compare this program with
a standard sibling or URD transplantation, with the aim of
showing comparable control of the leukemia and DFS. The
conditioning regimen will need to be the same for all donor
types. The TBF program is more suitable for a multicenter
trial because it has shown equivalent efﬁcacy as TBI in our
preliminary experience, because TBI is not available in every
center, and it can bemodulated for older patients with a dose
reduction of busulfan.ACKNOWLEDGMENTS
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